Yahoo Web Search

Search results

  1. Orano Med seeks to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 (212Pb), a rare alpha-emitting radioisotope and one of the most potent therapeutic payloads against cancer cells. Discover our mission.

    • About us

      Orano Med seeks to develop a new generation of targeted...

    • Targeted Alpha Therapy

      Orano Med has equipped itself with all the tools necessary...

    • Pipeline

      Based on the unique properties of 212Pb, Orano Med is...

    • Industrial platform

      The patented, entirely chemical process, developed by Orano...

    • News

      By clicking “I accept Cookies”, you agree with the cookies...

    • Contact

      Orano Med Contact. By clicking “I accept Cookies”, you agree...

    • Careers

      Orano Med: Orano Med has developed new processes for...

  2. People also ask

  3. Feb 12, 2024 · Orano Med is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting...

  4. Feb 12, 2024 · RadioMedix, Inc. and Orano Med, two clinical stage radiopharmaceutical companies, today announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to AlphaMedix TM (212 Pb-DOTAMTATE) for the treatment of adult patients with unresectable or metastatic, progressive somatostatin receptor ...

  5. Mar 16, 2022 · Orano Med, a subsidiary of the Orano group, has taken important steps forward in the development of treatments known as "targeted alpha therapy" with lead-212, an innovative approach to fighting cancers with limited therapeutic options.

  6. Jan 3, 2022 · Orano Med is a clinical-stage biotechnology company with the ambition to develop a new generation of targeted therapies against cancer using the unique properties of lead-212 ( 212 Pb), a rare alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known as Targeted Alpha-Emmiter Therapy (TAT).

  7. www.macrocyclics.com › about › oranomedOrano Med - Macrocyclics

    Orano Med (previously AREVA Med) is Macrocyclics’ parent company since 2011. Orano Med is a nuclear biotech company developing innovative therapies in oncology.

  1. People also search for